At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
FBT First Trust NYSE Arca Biotechnology Index Fund
Market Closed 10-23 16:00:00 EDT
269.25
-3.43
-1.26%
盘后269.25
+0.000.00%
19:30 EDT
High271.54Low268.02Vol60.23K
Open271.54D1 Closing272.68Amplitude1.29%
Mkt Cap2.95BTradable Cap2.95BTotal Shares10.95M
T/O16.24MT/O Rate0.55%Tradable Shares10.95M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Corcept Therapeutics Down over 17%, on Pace for Largest Percent Decrease Since December 2025
Dow Jones  ·  02:40
Corcept Therapeutics Down over 17%, on Pace for Largest Percent Decrease Since December 2025
Moderna (MRNA) vs. BioNTech (BNTX): Which Biotech Stock Offers Upside, According to Wall Street?
TIPRANKS  ·  10-23 16:14
Moderna (MRNA) vs. BioNTech (BNTX): Which Biotech Stock Offers Upside, According to Wall Street?
Veracyte’s Decipher Test Predicts Abiraterone Benefit in Very High-Risk Prostate Cancer Study
Reuters  ·  10-23 16:00
Veracyte’s Decipher Test Predicts Abiraterone Benefit in Very High-Risk Prostate Cancer Study
Phase Iii Trial Shows Veracyte’s Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate Cancer
THOMSON REUTERS  ·  10-23 16:00
Phase Iii Trial Shows Veracyte’s Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate Cancer
October 2026's Top Insider-Owned Growth Stocks
Simply Wall St.  ·  10-21
October 2026's Top Insider-Owned Growth Stocks
Bruker Corporation Publishes Update to Financial Calendar
Reuters  ·  10-21
Bruker Corporation Publishes Update to Financial Calendar
Alkermes Schedules Third-Quarter Financial Results Call
Reuters  ·  10-21
Alkermes Schedules Third-Quarter Financial Results Call
Alkermes to Report Third Quarter Financial Results on November 3, 2026
THOMSON REUTERS  ·  10-21
Alkermes to Report Third Quarter Financial Results on November 3, 2026
OpenAI confirms acquisition of biopharma platform Orchestra Bio
TIPRANKS  ·  10-21
OpenAI confirms acquisition of biopharma platform Orchestra Bio
OpenAI acquires biotech startup Orchestra Bio, Axios reports
TIPRANKS  ·  10-21
OpenAI acquires biotech startup Orchestra Bio, Axios reports
Disc Medicine Stock (IRON) Soars Over 28% on a Phase 3 Trial Win
TIPRANKS  ·  10-19
Disc Medicine Stock (IRON) Soars Over 28% on a Phase 3 Trial Win
Veracyte Study Shows Decipher Test Predicts Abiraterone Benefit in Very High-Risk Prostate Cancer
Reuters  ·  10-19
Veracyte Study Shows Decipher Test Predicts Abiraterone Benefit in Very High-Risk Prostate Cancer
Press Release: $2.9 Million NCI Grant Awarded for Clinical Development of RedHill's Opaganib and CAR T-Cell Combination in Ultra-High-Risk Multiple Myeloma
Dow Jones  ·  10-19
Press Release: $2.9 Million NCI Grant Awarded for Clinical Development of RedHill's Opaganib and CAR T-Cell Combination in Ultra-High-Risk Multiple Myeloma
Six Studies to Highlight Veracyte’s Genomic Tests Across Breast, Prostate and Bladder Cancer at ESMO 2026
GlobeNewswire  ·  10-19
Six Studies to Highlight Veracyte’s Genomic Tests Across Breast, Prostate and Bladder Cancer at ESMO 2026
Analysts’ Top Healthcare Picks: Alkermes (ALKS), BridgeBio Pharma (BBIO)
TIPRANKS  ·  10-19
Analysts’ Top Healthcare Picks: Alkermes (ALKS), BridgeBio Pharma (BBIO)
Sensorion hires veteran gene therapy leader Peter Weber as Chief Medical Officer
TIPRANKS  ·  10-19
Sensorion hires veteran gene therapy leader Peter Weber as Chief Medical Officer
Corcept Therapeutics Director James N. Wilson Reports Sale of $1.15 Million in Common Shares
Reuters  ·  10-17
Corcept Therapeutics Director James N. Wilson Reports Sale of $1.15 Million in Common Shares
Veracyte's Prosigna Breast Cancer Recurrence Test Gets Medicare Coverage
MT Newswires Live  ·  10-16
Veracyte's Prosigna Breast Cancer Recurrence Test Gets Medicare Coverage
Veracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence Test
THOMSON REUTERS  ·  10-16
Veracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence Test
Alkermes Plc : Truist Securities Reinstates Coverage with Buy Rating; Target Price $55
THOMSON REUTERS  ·  10-16
Alkermes Plc : Truist Securities Reinstates Coverage with Buy Rating; Target Price $55

Introduction

Company Name.
First Trust NYSE Arca Biotechnology Index Fund
Affiliated Markets:
ARCA
Listing Date:
--
Main Business:
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the securities that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of small, mid and large capitalization companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services.
Issue price:
--